Eurobio Scientific Société anonyme

ENXTPA:ALERS Stock Report

Market Cap: €258.6m

Eurobio Scientific Société anonyme Valuation

Is ALERS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALERS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALERS (€25.85) is trading below our estimate of fair value (€59.9)

Significantly Below Fair Value: ALERS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALERS?

Key metric: As ALERS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALERS. This is calculated by dividing ALERS's market cap by their current earnings.
What is ALERS's PE Ratio?
PE Ratio39.1x
Earnings€6.64m
Market Cap€258.62m

Price to Earnings Ratio vs Peers

How does ALERS's PE Ratio compare to its peers?

The above table shows the PE ratio for ALERS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.2x
GNFT Genfit
9.2x41.2%€202.4m
OSE OSE Immunotherapeutics
4.2x-72.5%€193.4m
ALGEN genOway Société anonyme
27.1xn/a€33.9m
BOI Boiron
20.4x26.2%€487.9m
ALERS Eurobio Scientific Société anonyme
39.1x29.0%€258.6m

Price-To-Earnings vs Peers: ALERS is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the peer average (15.2x).

Price to Earnings Ratio vs Industry

How does ALERS's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ALERS 39.1xIndustry Avg. 27.0xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALERS is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the European Biotechs industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is ALERS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALERS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.1x
Fair PE Ratio19.9x

Price-To-Earnings vs Fair Ratio: ALERS is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€116.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€92.79

7D

1.4%

1Y

7.1%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

0%

1Y

-56.6%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€47.41

7D

4.0%

1Y

-10.6%